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Abstract
1. The purpose of this study was to compare the enzymatic kinetics and distribution of cytochrome
P450 2D (CYP2D) among different rat brain subcellular fractions.
2. Rat brains were used to prepare total membrane, crude mitochondrial, purified mitochondrial,
and microsomal fractions, in addition to total homogenate. Michaelis-Menten kinetics of the
brain CYP2D activity was estimated based on the conversion of dextromethorphan (DXM) to
dextrorphan using UPLC-MS/MS. Protein levels of CYP2D and subcellular markers were
determined by Western blot.
3. Microsomal CYP2D exhibited high affinity and low capacity, compared with the mitochondrial
CYP2D that had a much lower (~ 50-fold) affinity but a higher (~six-fold) capacity. The
apparent CYP2D affinity and capacity of the crude mitochondria were in between those of the
microsomes and purified mitochondria. Additionally, the CYP2D activity in the whole
homogenate was much higher than that in the total membranes at higher DXM concentrations.
A CYP2D immune-reactive band in the brain mitochondria appeared at a lower MW but had
a much higher intensity than that in the microsomes.
4. Mitochondrial brain CYP2D has a much higher capacity than its microsomal counterpart.
Additionally, brain homogenate is more representative of the overall CYP2D activity than the
widely-used total membrane fraction.
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Introduction
Cytochrome P450 (CYP450) 2D6 (CYP2D6) is an isoform of the CYP450 superfamily of drug
metabolizing enzymes, which is responsible for the metabolism of many centrally-acting drugs
and neurotransmitters (McMillan & Tyndale, 2018; Miksys & Tyndale, 2002; Navarro-Mabarak
et al., 2018; Sangar et al., 2009; Wang et al., 2014). The rat CYP2D subfamily shares homology
with human CYP2D6, resulting in significant overlap in substrate specificity amongst rat
CYP2D1-5 isoforms and human CYP2D6 (Hiroi et al., 2002; Miksys et al., 2000; Tyndale et al.,
1999). While mRNA studies have shown that CYP2D4 is the predominant isoform in the rat brain
(Funae et al., 2003; Hiroi et al., 1998), other isoforms of CYP2D, such as 2D1 or 2D5, have also
been detected in the rat brain, albeit at much lower concentrations (Miksys et al., 2000; Mizuno et
al., 2003; Wyss et al., 1995). Studies with rats and monkeys have shown that the concentration and
pharmacological response of analgesics and antipsychotics are better correlated with the variability
in CYP2D enzyme activity in the brain, as opposed to the hepatic CYP2D (McMillan & Tyndale,
2015; Wang et al., 2015; Zhou et al., 2013). Additionally, induction of brain CYP2D can be
independent of its expression in the liver (Mann et al., 2008; Yue et al., 2008). The genomic
variation in CYP2D6 in humans has been correlated with behavioral and psychopathological
patterns and is speculated to be related to CYP2D’s involvement in the biotransformation of
serotonin and dopamine (Penas-Lledo & Llerena, 2014). Therefore, investigation of the brain
CYP2D expression and activity is crucial to our understanding of the effects of centrally-acting
drugs and diseases associated with the changes in the synthesis of neurotransmitters.
Mechanistic studies of CYP450 in brain are more complicated than those in the liver, which
is the major organ for CYP450-mediated drug metabolism. This is due to the overall low
concentrations of CYP450 enzymes, such as CYP2D, in the brain, which makes quantification of
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their metabolic activities difficult (Toselli et al., 2016). Additionally, there is heterogeneity in the
expression of CYP2D within the cells and between different regions of the brain (McMillan &
Tyndale, 2018; Toselli et al., 2016). To overcome these obstacles, many studies have pooled brains
from several rodents to obtain enough tissue for characterization of CYP2D activity (Asai et al.,
2018; Coleman et al., 2000; Jolivalt et al., 1995; Voirol et al., 2000). Others (Mann et al., 2008;
Toselli et al., 2016; Yue et al., 2008) have relied on methods like RT-PCR and/or Western blotting,
instead of enzymatic activity, to estimate changes in the brain CYP2D status. Those studies that
have successfully measured functional activity of brain CYP2D utilizing probe substrates, such as
dextromethorphan (DXM), tend to either focus on microsomal activity (Asai et al., 2018; Coleman
et al., 2000; Jolivalt et al., 1995; Voirol et al., 2000) or something called a “total membrane”
fraction (McMillan & Tyndale, 2017; Miksys et al., 2017; Tyndale et al., 1999; Zhou et al., 2013),
which is a pooling of all membranes, including microsomes and mitochondria.
Although brain CYP2D is expressed in both endoplasmic reticulum (i.e., microsomes) and
mitochondria (Miksys et al., 2000; Tyndale et al., 1999), it should not be assumed that its
functionality in a total membrane fraction would be an accurate reflection of that in the individual
subcellular fractions or the entire cell. This is because CYP450 enzymes in different subcellular
compartments

utilize

different

reductases

for

transferring

electrons

from

NADPH

(Anandatheerthavarada et al., 1997; Boopathi et al., 2000; Dasari et al., 2006), which may or may
not be available to the same extent in the total membrane fraction. Therefore, the information
obtained from the studies of CYP2D activity in the total membrane fractions may not be easily
extrapolated to the activity of this enzyme in the cell.
Despite recognition of the presence of CYP2D in the brain mitochondria (Miksys et al.,
2000; Tyndale et al., 1999), a complete characterization of mitochondrial CYP2D activity,
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including its Michaelis-Menten (MM) kinetics are absent from the literature. Furthermore, we are
not aware of any comparison of the kinetics of CYP2D activity among commonly-used subcellular
fractions in the same brain sample. Therefore, the major aim of this study was to determine the
kinetics of DXM demethylation in the rat brain microsomal, mitochondrial, and total membrane
fractions in a side-by-side comparison. Considering mitochondria can vary in purity, we also
compared Percoll-gradient purified mitochondria to unpurified “crude” mitochondria. Further, the
kinetics of CYP2D activity was investigated in the whole brain homogenate as a potential
alternative to the total membrane fraction. In addition to the kinetic studies of the enzymatic
activity, we also measured the protein content of CYP2D in different subcellular fractions using
Western blot analysis to determine if any correlations exist between enzymatic activity and
CYP2D content.

Methods
Chemicals and antibodies
Dextromethorphan (DXM) was purchased from United States Pharmacopeial Convention
(Rockville, MD, USA). Analytical metabolite standard solutions for dextrorphan tartrate (DXT)
and its stable isotope d3-dextrorphan were purchased from Cerilliant Corporation (Round Rock,
TX, USA). Primary antibodies raised in rabbit against CYP2D1 (ab22590), calreticulin (ab92516),
and voltage-dependent anion-selective channel 1 (VDAC1)/Porin (ab15895) were purchased from
Abcam (Cambridge, MA, USA). Although the CYP2D1 antibody is raised against CYP2D1, it
should be noted that because of significant homology (77% to 83%) among rat CYP2D isoforms
1-5 (Funae et al., 2003), it is very likely that the antibody reacts with other rat CYP2D isoforms as
well. The fluorescent secondary antibody Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 680) and
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HRP-conjugated Goat Anti-Rabbit IgG H&L were purchased from Abcam. All other reagents and
chemicals were analytical grade and purchased from commercial sources.
Preparation of subcellular fractions from whole rat brain
Although separate protocols are reported in the literature for preparation of brain total membrane
(Miksys et al., 2000), crude and purified mitochondrial (Kristian, 2010), and microsomal (Bhagwat
et al., 1995; Jolivalt et al., 1995; Voirol et al., 2000) fractions, to the best of our knowledge, there
is no single protocol for preparation of all the fractions from the same brain tissue. Thus, the
protocols from these different studies were adapted into a single procedure to generate all four
fractions, which necessitated some modifications to the homogenization and storage buffer
compositions, as described below.
Frozen whole brains from adult (8 to 12-week old), male Sprague-Dawley rats were
purchased from Innovative Research (Novi, Michigan, USA). Pooled whole brains (2 brains per
preparation) were homogenized in ice-cold buffer (100 mM Tris, 0.2 mM EDTA, and 1.15% KCl;
pH 7.4) at a 1:10 ratio using an electric motor-driven Potter-Elvehjem Teflon homogenizer. The
homogenate was divided into two tubes. One tube was used to generate the crude mitochondrial
(CM) and total membrane (TM) fractions. The other tube was used for collection of purified
mitochondria (PM) and microsomes (MC). Each homogenate tube was first spun at 1300 g for 5
minutes at 4oC. The supernatant was collected, and the pellet washed with the homogenizing buffer
and centrifuged again at 1300 g for 5 minutes. For each tube, the original and wash supernatants
were combined and used for the preparation of the individual fractions as described below. A total
of 5 preparations were made from 5 different brain pools, with 4 fractions per preparation.
The collected pellets from each respective fraction, prepared as described below, were resuspended in storage buffer (100 mM Tris, 0.2 mM EDTA, 1.15% KCl, 20% glycerol, 0.1 mM
dithiothreitol, 22 µM butylated hydroxytoluene, and 0.1 mM phenylmethylsulfonyl fluoride; pH
5

7.4) (Bhagwat et al., 1995) and stored at -80oC for later experiments. Total protein concentrations
were estimated using the Bradford method.
Total membranes (TM)
The 1300-g supernatant was spun at 110,000 g for 70 minutes at 4oC. The supernatant was
discarded, and the pellet was washed and centrifuged again using fresh homogenization buffer.
The TM pellet was then collected and re-suspended in the storage buffer.
Crude mitochondria (CM)
The 1300-g supernatant was spun at 21,000 g for 12 minutes at 4oC. The supernatant was discarded
and the pellet was washed and centrifuged again using fresh homogenization buffer. The CM pellet
was collected and re-suspended in the storage buffer.
Purified mitochondria (PM)
The crude mitochondrial pellet was generated as described above. The pellet was re-suspended in
the homogenization buffer with 15% Percoll and run twice on a 15%/24%/40% Percoll gradient,
which was spun at 30,700 g for 12 minutes at minimal acceleration and no brakes. The layer
containing PM, at the interface between the 24% and 40% Percoll layers, was collected and washed
3 to 4 times, with the homogenization buffer by spinning at 21,000 g. The final non-synaptic PM
pellet was re-suspended in the storage buffer.
Microsomes (MC)
The 1300-g supernatant was spun at 21,000 g for 12 minutes at 4oC. The supernatant was collected
and spun at 110,000 g for 70 minutes. The pellet was washed and centrifuged again using fresh
homogenization buffer. The MC pellet was collected and re-suspended in the storage buffer.
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Preparation of whole homogenate (WH)
In addition to the four individual fractions above, we also prepared WH from additional 5 rat brains
in a separate experiment. Individual, frozen rat brains were homogenized at a 1:10 ratio in the
homogenization buffer as described above and stored at -80oC.
Dextromethorphan O-demethylase activity
The assay for dextromethorphan O-demethylase (DOD) activity was carried out in a 100 mM TrisHCl buffer (pH 7.4) and a protein concentration of 0.2 mg/mL. For these assays, DXM stock
solutions were prepared by dissolving the powder in 5 mM excess HCl solutions. For MC and TM
fractions, DXM concentrations were 100, 200, 500, 1000, 1500, and 2000 µM, whereas the activity
in WH, CM, and PM was measured at substrate concentrations of 100, 200, 500, 1000, 2000, 5000,
and 10000 µM. The reaction mixtures (25 µL) contained buffer, sample protein, and substrate.
After 5 minutes preincubation at 37oC, the reaction was initiated by the addition of 1 mM NADPH.
After 20 minutes incubation at 37oC, reactions were terminated by the addition of ice-cold
acetonitrile (75 µL), containing internal standard. Each reaction mixture was paired with its own
control sample (time zero), containing all the elements of the reaction mixture with the exception
of NADPH. The reactions in the control samples were immediately terminated by the addition of
ice-cold acetonitrile containing internal standard. Samples were centrifuged, and the supernatant
was used for LC-MS/MS analysis.
UPLC-MS/MS analysis of dextromethorphan metabolite
The sample preparation for the analysis of DXT consisted of precipitation of proteins in the
reaction mixture (25 µL) by the addition of 75 µL of ice-cold acetonitrile, containing 10 nM
internal standard (d3-dextrorphan). Samples were then vortexed, centrifuged at 13,400 rpm for 5
minutes, and the supernatant collected for the LC-MS/MS analysis.
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The concentrations of DXT in the subcellular fractions were quantitated using a validated
UPLC-MS/MS method (DuBois & Mehvar, 2018). Briefly, the UPLC-MS/MS system consisted
of a Kinetex 1.7 µm C18 (100 A, 100 x 2.1 mm) column (Phenomenex; Torrance, CA, USA),
connected to a Bruker (Billerica, MA, USA) EVOQ triple quadrupole mass spectrometer. Samples
(2 µL) were injected onto the column and eluted at a flow rate of 0.2 mL/min at 40oC under gradient
conditions with 5 mM ammonium formate and 0.05% formic acid in water (A) and 95%
acetonitrile, 5% methanol, and 0.05% formic acid (B). Gradient conditions were as follows: 0-0.5
minutes, 10% B; 0.5-4 min, linear gradient 10-90% B; 4-7 min, 90% B; 7 min, 10% B; 7-9 min,
10% B. Retention time for DXT and its stable isotope was 2.75 minutes. The source utilized heated
electrospray ionization (needle temperate 3000C, flow 40 psi; cone temperature 3000C, flow 20
psi; nebulizer gas flow 50 psi) in positive ion mode at 3000 V. Metabolite and internal standard
were analyzed using selected reaction monitoring for the parent/fragment transitions of m/z 258
à 156.90 for DXT and m/z 261 à 156.90 for d3-DXT. The standard curve for DXT was linear
between 0.25 to 100 nM (r2 ≥ 0.99) with lower limit of quantitation of 0.25 nM and inter- and intraday accuracies between 94.1 to 111% and precision (relative standard deviation) values of ≤14.9%.
Immunoblotting experiments
Proteins (3-15 µg) from subcellular fractions were subjected to SDS-polyacrylamide gel
electrophoresis on a precast Bio-Rad (Hercules, CA, USA) 4-20% MP TGX Stain-Free gels for
CYP2D1 or 12% MP TGX gels for calreticulin and VDAC at constant voltage (200 V) for 30
minutes. Proteins were transferred with the Bio-Rad Trans-Blot Turbo Transfer System onto 0.45
µm (CYP2D1) or 0.20 µm (calreticulin and VDAC) PVDF membranes. Membranes were blocked
with 3% blotting grade, non-fat milk (CYP2D1) or 5% BSA (calreticulin and VDAC) for 1 hour
at room temperature, then incubated overnight with primary antibody for CYP2D1 (1:1,000),
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calreticulin (1:10,000), or VDAC (1:50,000). After washing, membranes were incubated with
fluorescent (CYP2D, 1:5,000) or HRP-conjugated (calreticulin and VDAC, 1:50,000) secondary
antibodies for 1 hour at room temperature, then washed before visualization of bands with the BioRad ChemiDoc Imager system.
Data analysis
Because of presence of some impurities of DXT in the DXM stock solution (DuBois & Mehvar,
2018), the rate of production of the metabolite was corrected by subtracting the amount of
metabolite in the control sample (time zero) from that in the sample after 20 min of incubation.
The metabolism rate-substrate concentration profile for each subcellular fraction was fitted to the
following three models.
Single-enzyme, MM model
This model fits the DOD rate (V)-substrate concentration (S) data to a single-enzyme system with
MM parameters of maximum velocity (Vmax) and MM constant (Km):
𝑉=

#$%& ×(
)$ *(

(1)

Two-enzyme, MM model
This model fits the DOD rate-substrate concentration data to a two-enzyme system with MM
parameters of Vmax1 and Km1 for the first enzyme and Vmax2 and Km2 for the second enzyme:
𝑉=

#$%&+ ×(
)$+ *(

+×

#$%&- ×(
)$- *(

(2)

Two-enzyme, mixed model
This model uses a two-enzyme system, one with a MM behavior with parameters of Vmax1 and Km1
and the other with a linear behavior within the studied substrate range with an intrinsic clearance
of CLint2:
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𝑉=

#$%&+ ×(
)$+ *(

+ (𝐶𝐿1234 × 𝑆)

(3)

The best fit model describing the experimental data for each subcellular fraction was
selected based on the evaluation of Eadie-Hofstee transformed plots and the Akaike’s Information
Criterion (AIC). Additionally, the intrinsic clearance (CLint) for each enzyme system with MM
characteristics was calculated by dividing Vmax by Km of the enzyme.
Statistical analyses were performed with repeated measure, one-way ANOVA, followed
by Tukey’s post-hoc test, or with unpaired, two-tailed t-tests. A p value of < 0.05 was considered
significant. Data are presented as mean ± SD. Statistical and nonlinear regression analyses were
performed with GraphPad Prism (v7.04) software (La Jolla, CA, USA).

Results
Dextromethorphan O-demethylase activity in subcellular fractions
Figure 1A depicts the kinetics of DOD activity in the microsomal (MC), crude mitochondrial
(CM), and purified mitochondrial (PM) fractions. Based on both Eadie-Hofstee plots and AIC
(data not shown), all the individual microsomal (MC) and purified mitochondrial (PM) fractions
were best described by the single-enzyme, MM model. Similar to the MC and PM fractions, AIC
also suggested the single-enzyme model as the best fit model for the crude mitochondrial (CM)
samples. However, the Eadie-Hofstee plots were more ambiguous as some CM samples showed
signs of nonlinearity, which is an indication of presence of multiple enzymes. Nevertheless,
because of lack of sufficient number of data points to accurately estimate the parameters of a multienzyme system, we used the simpler single-enzyme model for the description of CM fraction data
as well. In microsomes, the metabolic rate plateaued between substrate concentrations of 1000 and
2000 µM (Fig. 1A). In contrast to the microsomes, the DOD activity of the crude and purified
mitochondrial fractions did not reach a clear plateau, even at substrate concentrations as high as
10

10,000 µM (Fig. 1A), which was the limit of solubility of substrate in our reactions. However, at
substrate concentrations ≤ 2000 µM, the crude and purified mitochondrial fractions exhibited
lower DOD activities relative to microsomes (Fig. 1A).
The activity-substrate concentration profiles in the whole homogenate (WH) and total
membrane (TM) fraction, which were best fit to the two-enzyme, mixed model (based on both
Eadie-Hofstee plots and AIC), are shown in Fig. 1B. Whereas at substrate concentrations below
2000 µM, the relationship between the observed activity and substrate concentration was
nonlinear, there was an almost linear relationships between the two parameters at concentrations
between 2000 to 10000 µM (Fig 1B).
Figure 2 depicts the single-enzyme, MM parameters Vmax (Fig. 2A), Km (Fig. 2B), and
CLint (Fig. 2C) for the brain microsomal (MC), crude mitochondrial (CM), and purified
mitochondrial (PM) fractions. The estimated Vmax value (pmol/min/mg protein) for microsomes
(3.40 ± 0.28) was significantly (p < 0.05) lower than the corresponding values for the crude (8.35
± 1.87) or purified (19.4 ± 3.4) mitochondria (Fig. 2A). Indeed, the relatively high Vmax values for
both mitochondrial fractions were outside the observed experimental range of tested substrate
concentrations (Fig. 1A). However, purified mitochondria had a significantly higher Vmax,
compared with the crude mitochondria (Fig. 2A). Similarly, the Km values (µM) for the
microsomes (220 ± 24) were significantly lower than the values for the crude (6680 ± 2500) or
purified (10,500 ± 2320) mitochondria (Fig. 2B). Among all the fractions, purified mitochondria
had the highest apparent Km, but this was not significantly different from the value in the crude
mitochondria (Fig. 2B). As for the apparent CLint (µL/hr/mg), microsomes showed by far the
highest (p < 0.001) value (0.937 ± 0.149), when compared with the values in the crude (0.0776 ±
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0.0096) or purified (0.114 ± 0.030) mitochondria (Fig. 2C). However, there was no significant
difference in the CLint values between the crude and purified mitochondria.
Figure 3 depicts the parameters of the two-enzyme, mixed model, which was the best fit to
the total membrane (TM) fraction and whole homogenate (WH) data. For the first enzyme, the
estimated parameters (Vmax1, Km1, and CLint1) in the TM fraction were not significantly different
from those in the WH (Figs. 3A, 3B, and 3C). However, for the second enzyme, there was a
significant difference (p < 0.0001) between TM and WH in their CLint2 values (µL.hr-1.mg-1),
which were 2.4-fold higher in WH (0.0413 ± 0.004) than those in TM (0.0173 ± 0.003).
Subcellular localization of CYP2D and marker proteins CPR and VDAC
The Western blot data for CYP2D, VDAC, and calreticulin are presented in Figure 4. For CYP2D,
an immune-reactive band was observed in the brain microsomes (MC), which corresponded to the
same MW (~ 50 kDa) of the positive liver microsomal control (Fig. 4A, right panel). Additionally,
a less intense band was present at a lower MW in both the liver and brain MC (Fig. 4A, right
panel). In the total membranes (TM), crude mitochondria (CM), and purified mitochondria (PM),
an intense immune-reactive band was observed, which corresponded to the lower MW band in MC
(Fig. 4A, right panel). Because PM had the highest protein-corrected band intensity, the proteincorrected band intensities are presented as a percentage of the intensity in PM. The CYP2D band
intensities in the four brain fractions were in the following order: PM (100% ± 21%) > CM (33.8%
± 4.7%) = TM (33.6% ± 4.9%) > MC (5.3% ± 1.9%, higher MW band) (Fig. 4A, left panel). The
protein-corrected band intensity in PM was significantly higher than that in all the other fractions
(p < 0.001). The protein-corrected band intensities in CM and TM were not significantly different
from each other but were both significantly greater than the intensity of the higher MW band in
MC (p < 0.01).
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As expected, VDAC, an outer-membrane mitochondrial marker protein with a MW of ~31
kDa, was abundantly present in the brain mitochondrial fractions (Fig. 4B, right panel). Because
PM had the highest band intensity, the band intensities are presented as a percentage of intensity
in PM. The VDAC intensities in the four brain fractions were in the following order: PM (100% ±
36%) > CM (41.2% ± 8.2%) > TM (26.4% ± 1.3%) > MC (2.1% ± 0.6%) (Fig. 4B, left panel). The
VDAC intensities in all the four fractions were significantly different from each other (Fig. 4B,
left panel).
As expected, calreticulin, an endoplasmic reticulum marker protein, was abundantly
present in the brain MC and corresponded to the same MW (~75 kDa) of the positive liver
microsomal control sample (Fig. 4C, right panel). Because MC had the highest band intensity, the
band intensities of calreticulin are presented as a percentage of intensity in the brain MC. The
calreticulin intensities in the four brain fractions were in the following order: MC (100% ± 14.8%)
> TM (63.5% ± 14.2%) > CM (42.2% ± 10.3%) > PM (15.7% ± 5.6%) (Fig. 4C, left panel). The
calreticulin intensities in all the four fractions were significantly different from each other (Fig.
4C, left panel).

Discussion
The recent evidence about the therapeutic and pathophysiologic relevance of brain CYP2D calls
for a new evaluation of this enzyme’s metabolic behavior related to its subcellular distribution.
Despite presence of significant quantities of this enzyme in mitochondria (Miksys et al., 2000;
Tyndale et al., 1999), the kinetics of the enzymatic activity of brain CYP2D in mitochondria have
not been characterized. Estimating these kinetic parameters would be useful in determining the
contribution of these subcellular compartments (endoplasmic reticulum or mitochondria) to the
CYP2D-mediated biotransformation of drugs and endogenous compounds in the brain. Therefore,
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the main goal of our study was to compare the brain CYP2D metabolic kinetics side-by-side
between the endoplasmic reticulum (microsomes) and mitochondria utilizing the DOD activity
assay. Our findings suggest that the kinetics of CYP2D-mediated enzymatic activity in the brain
are dramatically different between these two subcellular fractions (Figs. 1 and 2). Microsomes
exhibited a high affinity (low apparent Km), low capacity (low apparent Vmax) metabolic activity,
whereas purified mitochondria had a low affinity (high apparent Km), but a very high capacity
(high apparent Vmax). The finding of a high capacity CYP2D activity in the brain mitochondria is
novel, which may have therapeutic, pathophysiologic, and/or toxicologic relevance due to
contribution of brain CYP2D to the metabolism of centrally-acting drugs and synthesis of
neurotransmitters.
Abundance and activity of CYP2D in brain microsomes and mitochondria
Our immunoblot studies with the CYP2D antibody showed different patterns in the brain
microsomal and mitochondrial fractions (Fig. 4A). Whereas the microsomal fraction showed an
intense band at a higher MW and a much less intense band at a lower MW, the mitochondrial
fractions showed a very intense band at the lower MW (Fig. 4A, right panel). Interestingly, the
profile for the control liver microsomal sample was similar to that for the brain microsomes (Fig.
4 A, right panel). It has been reported that CYP2D antibodies cannot reliably distinguish among
isozymes within the rat CYP2D subfamily (CYP2D1-5), which have subtle variations in their
molecular weights (Miksys et al., 2000). Therefore, it is possible that different CYP2D isoforms,
with different MWs, are present in the rat brain mitochondria and microsomes.
Based on mRNA studies, the major CYP2D isoform in the rat brain is CYP2D4 (Funae et
al., 2003; Hiroi et al., 1998; Wyss et al., 1995). Additionally, CYP2D1/5 mRNA has also been
found in the rat brain although at much lower abundance (Miksys et al., 2000; Mizuno et al., 2003;
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Wyss et al., 1995). It has been reported (Miksys et al., 2000) that among the CYP2D isoforms, the
MW of CYP2D4 is the lowest. Because CYP2D4 protein is low or absent in the liver (Hiroi et al.,
1998), it is likely that the lower band in the liver microsomes (lower MW), which is much less
intense than the upper band, is related to CYP2D4 and the more intense upper band (higher MW)
is related to CYP2D isoforms other than CYP2D4. Similarly, whereas the more intense upper band
in the brain microsomes may be a reflection of CYP2D isoforms other than 2D4, the intense band
with the lower MW in the PM may be related to CYP2D4. This hypothesis is in agreement with
the significant abundance of the lower band (potentially related to CYP2D4) in the total membrane
fraction of rat brain, observed in our studies (Fig. 4A, right panel) and the reported (Funae et al.,
2003; Hiroi et al., 1998; Wyss et al., 1995) prominence of CYP2D4 mRNA in the rat brain.
However, more specific antibodies are needed to confirm this hypothesis.
In addition to having a lower MW, the CYP2D band in the mitochondrial samples was
much more abundant than the major CYP2D band in the microsomes (Fig. 4A). Indeed, the
protein-corrected intensity of the CYP2D band in the microsomes (upper band) was ~5% of that
in the purified mitochondria. Therefore, the higher apparent Vmax in the brain mitochondria relative
to microsomes (Fig. 2A) is consistent with the high abundance of CYP2D in mitochondria (Fig.
4A). In fact, the capacity of this enzyme in the pure mitochondrial fraction was difficult to saturate
even at substrate concentrations of 10,000 µM (Fig. 1A). These observations are consistent with
the initial and oft-cited studies of CYP450 in the brain, which observed several-fold greater
amounts of CYP450 in mitochondria (Bhagwat et al., 2000; Ghersi-Egea et al., 1993; Ghersi-Egea
et al., 1987). Furthermore, Miksys et al. (Miksys et al., 2000) also showed presence of intense
immunoreactive bands in both mitochondrial and microsomal fractions prepared from the rat
brains. However, in their studies, the lower band was much more intense than the upper band not
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only for mitochondria, but also for microsomes. Although this is consistent with our data for the
mitochondria, our CYP2D1 antibody reactive bands in the microsomes showed higher intensity
for the upper band (Fig. 4A). Differences in the electrophoresis conditions and selectivity of
antibodies towards different CYP2D isoenzymes might have been responsible for the apparent
differences between our Western blot data (Fig. 4A) and those of Miksys et al. (Miksys et al.,
2000).
Despite high capacity, the mitochondrial DOD activity exhibited a low affinity relative to
the microsomes (Fig. 2B) such that the apparent intrinsic clearance (Vmax/Km) in purified
mitochondria was almost 9 times lower than that in the microsomes (Fig. 2C). Although studies
have observed overall higher CYP450 content in mitochondria (Bhagwat et al., 2000; Ghersi-Egea
et al., 1993; Ghersi-Egea et al., 1987), these same studies have also observed either similar or
lower activities relative to microsomes. Voirol et al. (Voirol et al., 2000) reported that the DOD
activity in the rat brain mitochondria was much lower than that in the microsomes. However, they
used substrate concentrations up to 600 µM DXM. This is consistent with our results at substrate
concentrations below 2000 µM (Fig. 1A). However, our DOD kinetic studies clearly show for the
first time that at higher substrate concentrations, enzymatic activity of the purified mitochondrial
fraction is several-fold higher than that of the microsomal fraction (Fig. 1A).
In addition to the possibility of the presence of a different CYP2D isoform in the
mitochondria, other factors may have also contributed to the apparent lower affinity of
mitochondrial CYP2D observed in our study. For instance, post-translational modification of
CYP2D for targeting to the mitochondria (Anandatheerthavarada et al., 1999; Boopathi et al.,
2000; Dasari et al., 2006) may affect its affinity. Another contributing factor to the lower affinity
in the mitochondria might be related to the major differences between the mitochondria and
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microsomes in their CYP450 electron transferring mechanisms. In the microsomes, cytochrome
P450 reductase (CPR) is responsible for the electron transfer to CYP450, and both CYP450 and
CPR are integrally membrane-bound proteins. However, the electron transfer system in
mitochondria consists of two soluble proteins, adrenodoxin (Adx) and adrenodoxin reductase
(Adr), which are present in the inner membrane matrix. During the preparation of mitochondrial
fractions, it is possible that the inner and/or outer membranes of some mitochondria are disrupted,
resulting in a reduction in the concentrations of Adx and Adr proteins in the mitochondrial matrix
(Dasari et al., 2006; Sangar et al., 2009). Consequently, the apparently low affinity (Fig. 2B) and
intrinsic clearance (Fig. 2C) of the CYP2D-mediated DOD in mitochondria, compared with the
respective values in the microsomes, could be partially related to some loss of Adx and Adr during
the preparation of mitochondria.
Subcellular fraction purity
Because of the nature of differential centrifugation, there is always some degree of contamination
of various subcellular fractions prepared by this method. Therefore, we used VDAC, a
mitochondrial marker, to determine the contamination of microsomes by mitochondria, and
calreticulin, a microsomal marker, to estimate the degree of contamination of purified
mitochondria by microsomes. As the data in Fig. 4B indicate, the degree of contamination of
microsomes with mitochondria, based on VDAC presence, was negligible (~ 2%). Additionally,
the degree of contamination of Percoll-purified mitochondrial fraction with microsomes, based on
calreticulin presence, was ~16% (Fig. 4C). These data suggest that the enzymatic activities (Figs.
1 and 2) and CYP2D band intensities (Fig. 4A) in the microsomal and Percoll-purified
mitochondrial fractions are relatively accurate measures for these two fractions.
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Because crude, instead of purified, mitochondria is commonly used in brain CYP450
studies (Ghersi-Egea et al., 1993; Lavandera et al., 2015; Miksys et al., 2000; Voirol et al., 2000),
we also investigated the CYP2D activity and expression in this fraction. As expected, the crude
mitochondrial fraction had a higher degree of microsomal contamination (42%) than the Percollpurified mitochondria (16%), based on calreticulin (Fig. 4C). This microsomal contamination
could explain the significantly lower Vmax and Km values (Figs. 1 and 2) and band intensity (Fig.
4A) for the crude mitochondria relative to those for the purified mitochondria. These data suggest
that studies that use crude mitochondrial fraction may not accurately reflect the true metabolic
characteristics of the mitochondrial CYP2D in the brain.
Despite presence of 42% microsomal impurity, the CM fraction only showed one band at
the lower MW, corresponding to that in the PM fraction (Fig. 4A, right panel). The lack of a visible
upper microsomal band in the CM fraction might be explained by the fact that the upper band in
the MC fraction was equivalent to only 5% of the CYP2D band in the pure mitochondria (See
Abundance and activity of CYP2D in brain microsomes and mitochondria). Therefore, in the
presence of substantial mitochondrial band in the CM fraction, the upper band related to the
microsomal impurity may not be easily visible.
The total membrane fraction versus brain homogenate
Many studies of the brain CYP450 isoforms have used a total membrane fraction as an overall
measure of the brain activity/content (Agarwal et al., 2008; Mann et al., 2008; McMillan &
Tyndale, 2015; Miksys et al., 2000; Miksys et al., 2017; Tyndale et al., 1999; Wu et al., 2011).
This is because the total membrane fraction would contain all the functional cellular CYP450,
which are membrane bound proteins. However, it is not known how the total membrane fraction
would compare with the whole brain homogenate, which is easily and quickly prepared without
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any ultracentrifugation process. Because of the presence of several DXM-metabolizing subcellular
compartments in both TM and WH, a simple, one-enzyme system could not fit the data for these
preparations. Instead, a two-enzyme, mixed model with an apparent MM kinetics, to describe the
early phase (lower DXM concentrations), and an apparent linear model, to describe the late phase
(higher DXM concentration), was necessary (Fig. 1B).
Our data with the MC and PM fractions (Fig. 1A) suggest that whereas the kinetic profiles
of TM and WH at lower DXM concentrations are mostly influenced by its microsomal content,
the mitochondrial fraction would likely dominate the profiles at the higher DXM concentrations
(Fig. 1B). Therefore, similarity of the TM and WH profiles at lower DXM concentration (Fig. 1B),
associated with the similar MM parameters for the first enzyme (Fig. 3), suggest that the
contribution of microsomes to the metabolism of DXM is similar in TM and WH. However, the
lower CYP2D activity in the TM fraction, compared to that in WH, at high substrate concentrations
(Fig. 1B), along with the significantly lower Clint2 value in TM (Fig. 3D), suggests that the
mitochondrial membranes present in the TM fraction are less active than the mitochondrial
structures present in WH.
The differences between TM and WH in their DOD activity might be related to the extent
of availability of the electron-donating systems in these preparations. Whereas the membranebound microsomal CPR is expected to be fully present in both TM and WH, the soluble
mitochondrial Adx and Adr may be lower or absent in the TM fraction because of the
centrifugation process and sheer stress (Wattiaux-De Coninck et al., 1974). Therefore, the
mitochondrial CYP2D in TM might be less active than its counterpart in WH. Collectively, our
data suggest that the whole brain homogenate might be superior to total membrane fractions as an
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overall measure of the metabolic activity of CYP2D, and potentially other CYP450 isoforms, in
the rat brain.
Although we are not aware of any other study reporting the kinetics of DOD activity in the
rat brain homogenate, the kinetics of DOD activity in the rat brain total membrane have been
reported before (Tyndale et al., 1999). That study (Tyndale et al., 1999) used a two-enzyme (MM)
model to fit the data in a substrate concentrations range of 0.5 to 600 µM. The activity-substrate
concentration profile in the study of Tyndale et al. was similar to the profile observed in our study
at concentrations below 600 µM (Fig. 1B). Additionally, our estimates for the apparent Vmax1 and
Km1 in the total membrane fraction (Fig. 3) were similar to the high-capacity, low affinity enzyme
in their two-enzyme system (Tyndale et al., 1999). However, our study, which included a much
higher substrate concentration range of 10,000 µM (as opposed to 600 µM), clearly identified a
much higher capacity enzyme. Collectively, these data indicate that the kinetics of DOD activity
in the total membrane fraction is very complex, due to presence of membranes and enzymes from
several different subcellular compartments and their interactions. Therefore, the models that best
fit the data depend on the studied substrate concentration range and may not be a true reflection of
available enzymes and their characteristics.
Comparison of DOD activity with CYP2D-mediated metabolism of other substrates
In addition to the available kinetic data on the DOD activity in the rat brain microsomes, a previous
study (Coleman et al., 2000) also reported the kinetics of metabolism (1'-hydroxylation) of
bufuralol, a known substrate for the human CYP2D6 enzyme, in the rat brain microsomes. The
authors showed that the kinetics of bufuralol 1'-hydroxylation in the rat brain microsomes was best
described by a two enzyme model, one with MM characteristics and the other with a Hill function.
However, the previous studies (Jolivalt et al., 1995; Voirol et al., 2000) and our own data (Fig.
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1A) suggest a one-enzyme system in the rat brain microsomes when DXM is used as a substrate.
These differences could be due to the choice of substrate as well as the concentration ranges
studied. Furthermore, it was shown (Coleman et al., 2000; Wan et al., 1997) that different isoforms
of rat CYP2D may have different substrate specificity. Studies in yeast cells expressing rat
CYP2D1, 2D2, 2D3, and 2D4 showed whereas bufuralol 1'-hydroxylation was similar among the
four isoforms, CYP2D2 showed the highest debrisoquin 4-hydroxylation activity and CYP2D3
showed the highest lidocaine N-deethylation activity. We are not aware of any similar data about
the specificity or selectivity of different rat CYP2D isoforms towards DOD. Therefore, it remains
to be seen whether the kinetic differences in the DOD activity among different brain fractions
reported here may be extrapolated to other CYP2D substrates.

Conclusions
A side-by-side comparison of the kinetics of DOD activity in microsomal and purified
mitochondrial fractions revealed a novel, high capacity enzyme in the mitochondria with a Vmax
that is at least six-fold higher than that in the brain microsomes. Additionally, the kinetics of DOD
activity in the total membrane and crude mitochondrial fractions, which are commonly used in rat
brain studies of CYP2D-mediated metabolism, were dependent on their relative contents of
mitochondrial and microsomal compartments and their electron-donating proteins. Further, a
comparison of the total membrane fraction with whole homogenate suggests that the latter is a
more accurate representative of the overall brain tissue activity of CYP2D. It is concluded that
brain fractions containing mixtures of mitochondria and microsomes, such as total membranes,
could obfuscate true differences between these subcellular compartments in their CYP2D
activities. Further investigations are needed to determine the pharmacological or toxicological
relevance of the high capacity brain mitochondrial CYP2D characterized in our studies. Although
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mitochondria CYP2D may play a smaller role in the metabolism of therapeutic concentrations of
xenobiotics, it may have a more significant role in drug overdoses and/or pathophysiologic
conditions affecting mitochondria.
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LEGENDS TO FIGURES
Figure 1. Dextromethorphan O-demethylase activity as a function of substrate concentration in
the rat brain microsomes, crude mitochondria, and purified mitochondria (A) and in the whole
homogenate and total membranes (B). Incubations were carried out at 37oC with 0.2 mg/mL
protein for 20 minutes. Symbols and error bars represent the average and SD of the experimental
data, respectively (n = 5). The lines represent the best fit to the data based on a single-enzyme,
MM model (A) or two-enzyme, mixed model (B).
Figure 2. Estimated dextromethorphan-O-demethylation kinetic parameters of rat brain
microsomes (MC), crude mitochondria (CM), and purified mitochondria (PM). A single-enzyme,
MM model was used to estimate apparent maximum velocity (Vmax) (A), MM constant (Km) (B),
and intrinsic clearance (CLint) (C). The symbols and horizontal lines represent individual and
average data, respectively (n = 5). Statistical analyses were performed with repeated measures,
one-way ANOVA, followed by Tukey’s post-hoc test. *, p<0.05; **, p<0.01; and ***, p<0.001.
Figure 3. Estimated dextromethorphan-O-demethylation kinetic parameters of rat brain total
membranes (TM) and whole homogenates (WH). A two-enzyme, mixed model was used to
estimate apparent maximum velocity (Vmax1) (A), MM constant (Km1) (B), and intrinsic clearance
(CLint1) (C) for the first enzyme and CLint2 (D) for the second enzyme. The symbols and horizontal
lines represent individual and average data, respectively (n = 5). Statistical analyses were
performed with an unpaired, two-tailed t-test. ****, p<0.0001.
Figure 4. Immunoblot analysis of CYP2D (A), VDAC (B), and calreticulin (C) in microsome
(MC), purified mitochondria (PM), crude mitochondria (CM), and total membranes (TM) fractions
in rat brains. For each panel, densitometry data for individual samples (left) and representative
blots (right) are presented. For each protein, the densitometry data are presented as the percentage
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of the highest abundant fraction. The symbols and horizontal lines in the left panels represent
individual and average data, respectively (n = 5). Statistical analyses were performed with repeated
measure, one-way ANOVA, followed by Tukey’s post-hoc test. A p value of < 0.05 was
considered significant. Means with the same letter are significantly different from each other.
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